I don’t think pricing or manual vs automation is holding up approval. I think it will be useful, and helpful, but I do not think that is holding up marketing approval and in fact my own analysis says that given current improvement and benefit and that it can treat over 3 years it is already far cheaper than alternatives and can even potentially be approved at a higher price will still being justifiable both at NICE and via the FDA.
Market Data 
Markets 
AI
